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論    文    の    要    旨 
This thesis aims to design a tissue plasminogen activator installed redox-active nanoparticle (t-
PA@iRNP) for oxidative stress associated diseases, including ischemia-reperfusion injury and 
cancer therapeutics. The thesis is composed of five chapters. Summaries of each chapter are 
described as follows. 
Chapter 1 described general introduction of the present thesis concerning the disordered 
oxidative stress associated diseases especially ischemia-reperfusion injury and cancer. t-PA as the 
only one thrombolytic agent, the drawback of which and issues of ROS scavenging is described in 
detail. In order to overcome the shortcomings of t-PA and traditional antioxidant, t-PA@iRNP 
system in this thesis is also summarized.  
Chapter 2 describes synthesis of poly(ethylene glycol)-b-poly[4-(2,2,6,6-
tetramethylpiperidine-1-oxyl) aminomethylstryrene] (PEG-b-PMNT) redox block copolymer in 
detail and preparation of t-PA installed nitroxide radical-containing, self-assembled nanoparticles (t-
PA@iRNP). t-PA@iRNP showed high colloidal stability under physiological environment because 
of the strong hydrophobicity of the PMNT segment.  
Chapter 3 describes the therapeutic effect of t-PA@iRNP through synergistic effect of 
thrombolysis and antioxidant effects in ischemic stroke. t-PA@iRNP significantly suppressed 
increases in cerebral infarct volume and improved neurological deficit after brain ischemia. In 
addition, t-PA-induced subarachnoid hemorrhage was also suppressed by t-PA@iRNP treatment 
through elimination of overproduced ROS.  
Chapter 4 describes the therapeutic effect of t-PA@iRNP in colon cancer via synergistic effect 
of fibrinolysis and antioxidant effects. t-PA@iRNP treatment showed the greatest effect of tumor 
growth inhibition compared to free t-PA and iRNP individual treatment.  
Chapter 5 describes that fibrinolytic t-PA as a new anti-tumor drug. t-PA treatment shows 
significantly anti-tumor effect in early and medium stages compared to control with negligible 
effects on the mouse body weight. In addition, fibrin deposition in colon tumor tissue was confirmed, 
t-PA depleted fibrin deposition, which improved classical activation macrophage M1 penetration 
with the inflammation promotion and cancer cells apoptosis properties in tumor tissues and inhibit 
tumor growth. 
In an effort to improve the t-PA-installed nitroxide radical-containing, pH-sensitive self-
assembled polyion complex nanoparticles (t-PA@iRNP) for ischemic stroke and cancer therapy, I 
have achieved four major advancements that provide a detailed insight and enhance the therapeutic 
performance of the system. First, the polyion complex afforded an optimized structure that stably 
loaded with low-dose t-PA and equipped with ROS-scavenging ability. Second, the synergistic effect 
of thrombolysis and antioxidant of t-PA@iRNP treatment was proved to significantly suppress an 
increase in infarct volume and improve neurological deficit in cerebral ischemia-reperfusion model 
mice in vivo. Third, t-PA@iRNP showed higher anti-tumor efficacy in a colon cancer mouse model, 
which was accompanied with decreased fibrin deposition, ROS level, tissue factor and attenuated 
NF-κB signaling in the tumors. Fourth, t-PA is potential as a new anti-tumor drug in the early and 
medium stage of tumor progression, which is anticipated to easily degrade fibrin deposition and 
increases the immune cells penetration in tumor tissues, providing a safe and specific inhibition of 
tumor growth. In summary, an advanced systemic configuration of t-PA-encapsulated nitroxide 
radical-containing, pH-sensitive self-assembled polyion complex nanoparticles for thrombolysis 
and anti-oxidant features in ischemia-reperfusion injury and anti-tumor efficacy in a colon cancer 
mouse model were successfully discovered, and these will strongly impact the new biomaterials 
field. Based on these results, further research into the clinical application of this system is warranted.  
 
審    査    の    要    旨 
〔批評〕 
There are several question such as stability of t-PA@iRNP, fluorescent quenching mechanism, different 
between separate administration and complex, administration conditions, size and macrophage population, 
and She explained clearly about this. Finally, reviewing committee members and other audience understand 
well. 
 
〔最終試験結果〕 
  2019 年 8 月 19 日、数理物質科学研究科学位論文審査委員会において審査委員の全員出席のも
と、著者に論文について説明を求め、関連事項につき質疑応答を行った。その結果、審査委員全員によ
って、合格と判定された。 
 
〔結論〕 
 上記の論文審査並びに最終試験の結果に基づき，著者は博士（工学）の学位を受けるに十分な資格
を有するものと認める。 
